I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were
La Paulee is traditionally the party/feast after harvest and a time when hard work is rewarded with food, fun, and wine. And so it was that evening; after better understanding genes, cytokines, and pathology it was time to have a good time with friends, old and new.
Drs. Mease, Cush and Ruderman: Psoriatic Arthritis
Drs. Philip Mease, Jack Cush and Eric Ruderman hold a panel discussion on the best of psoriatic arthritis at the ACR/ARHP Meeting in Chicago.
ǝlʇʇıɥʍ ɯɐs samwhittle
8 years ago
Final presentation of #ACR18 - Marissa Lassere presenting #ARAD data on opioid use in Australians with inflammatory arthritis. Use of high-potency opioids more likely in socioeconomically disadvantaged RA patients.
#SDOH
@RheumNow
Arthur Lau ArthurRheum
8 years ago
Bimekizimab phase 2 presented at #ACR18 with extremely impressive results for joints and skin improvement (in fact the primary outcome was ACR50!!!).... game changer? @RheumNow https://t.co/3lKkIMiSCI
Arthur Lau ArthurRheum
8 years ago
Pooled analysis from 3 PSA+12 PSO trials on ixekizumab RCTs. Reassuring that incidence of IBD relatively low with significant pt year f/u (https://t.co/icWfGIEnxt @RheumNow #ACR18
Dr. John Cush RheumNow
8 years ago
Now available: https://t.co/QrHTupEmaN. #acr18 https://t.co/N7dWlp3zz2
Arthur Lau ArthurRheum
8 years ago
SEAM PSA study: wow MTX monotherapy was surprisingly good for ACR scores (ETN clearly better especially for high bar outcomes, but not too shabby at all for MTX mono)
https://t.co/dc2vYFs8pY @RheumNow #ACR18
Arthur Lau ArthurRheum
8 years ago
ETN plus MTX combo better for skin PSO outcomes, but not a huge improvement for joints... but remember this study used ETN 50 q week (not twice weekly like used for PSO) @RheumNow
Suleman Bhana, MD DrBhana
8 years ago
LB abstract L06: Genovese et al. Filgotinib (JAK1-i) for treatment of RA after biologic failure. ACR 20/50/70 = 70/46/32% by 24 weeks. No GI perforations seen. #ACR18 @RheumNow https://t.co/5rAqz7ljXO
Suleman Bhana, MD DrBhana
8 years ago
Dr. Spiegal: Challenges in usability. in 2015 Cedars-Sinai allowed smartphone data to input into the EHR via Apple’s HealthKit framework. Out of nearly 80,000 invited patents, 499 connected (0.8%) = younger patients, few comorbidites, hospital employees. #ACR18 @Rheumnow https://t.co/HUPtbvGpVL
Suleman Bhana, MD DrBhana
8 years ago
Dr. Spiegal: Hyperpersonalize example of an app helping to increase activity level: “Today is a nice day outside, it will be good if you go out and go for a walk.”
#ACR18
Suleman Bhana, MD DrBhana
8 years ago
Dr. Spiegal: For reference: IDEAS (Integrate, Design, Assess, and Share) Framework and toolkit for development of effective digital interventions for health behavior. Mummah et al. J. Med Internet Research 2016. #ACR18 @RheumNow
Paul Sufka, MD psufka
8 years ago
This is an *extremely* important study in ANCA-vasculitis. Looking forward to really digging into this data. #ACR18 https://t.co/OX0YPwQrCD
Dr. Rachel Tate uptoTate
8 years ago
PET CT protocol with high NPV (98%)could be used as a first-line test to rule out GCA vs bx. https://t.co/yQEyQyHcDx @RheumNow #ACR18 L15


